Search

(GLOBE NEWSWIRE via COMTEX) -- - RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 - [...]

E stimated 23 million annual agitation episodes in the at-home setting [sup. 1-3 ] No FDA-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders [...]

GAITHERSBURG, Md., July 25, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ('BullFrog AI' or the 'Company'), a leader in AI-driven drug discovery, announced significant advancements in [...]

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies for acute treatment of agitation associated with [...]

LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) ('Compass'), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the [...]

(GLOBE NEWSWIRE via COMTEX) -- Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: [...]

Tianeptine's Mechanism of Restoring Neuroplasticity and Neurogenesis by Dual PPAR-B/δ and PPAR-γ Agonism Supports Development as a First-in-Class Oral Therapy for Psychiatric and Neurodegenerative Diseases Racemic Tianeptine, or TNX-601 ER, [...]

Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI(TM) Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates [...]

Pune India, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle [...]

Westford, USA, Sep 22, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END In the past few years, there has been a growing demand for treatment options for Bipolar Disorder Market. [...]

Dublin, June 03, Jun 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END The 'Global Bipolar Disorder Drugs and Treatment Market 2022-2032' report has been added to ResearchAndMarkets.com's offering. A [...]

NEW YORK, April 25, Apr 25, 2022 (GLOBE NEWSWIRE via COMTEX) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central [...]

Houston, March 24, Mar 24, 2022 (GLOBE NEWSWIRE via COMTEX) -- Houston, Texas - MindScape Ketamine & Infusion Therapy is bringing the benefits of IV Ketamine Infusion Therapy to the [...]

DUBAI, United Arab Emirates, Mar 22, 2022 (GLOBE NEWSWIRE via COMTEX) -- The global Bipolar Disorder Drugs And Treatment Market share, which was anticipated to be worth US$5.9 billion in [...]

Chicago, March 18, Mar 18, 2022 (GLOBE NEWSWIRE via COMTEX) -- Chicago, Illinois - IV Solution & Ketamine Centers Of Chicago is Chicago's first private facility to offer clinically proven [...]

NEW YORK, Dec 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults [...]

Los Angeles, USA, Jul 27, 2021 (GLOBE NEWSWIRE via COMTEX) -- Recent Advances in the Bipolar Depression Treatment | Bipolar Depression Clinical Trials Analysis Review Around 10+ key companies are [...]

NEW HAVEN, May 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the [...]

NEW YORK, May 03, May 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central [...]

NEW HAVEN, Mar 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- BioXcel Therapeutics, Inc. ('BioXcel' or the 'Company') (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative [...]

NEW YORK, Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- If approved, CAPLYTA has the potential to treat the broadest range of patients with bipolar depression. Intra-Cellular Therapies, Inc. [...]

KIELPIN, Poland, Jan 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) [...]

NEW HAVEN, Conn., Nov 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- Initiated rolling submission of New Drug Application ('NDA') with U.S. Food and Drug Administration ('FDA') On track to submit [...]

NAPERVILLE, Ill., Oct 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel liquid oral [...]

Jul 31, 2017 (M2 EQUITYBITES via COMTEX) -- H. Lundbeck A/S (CPH:LUN), a global pharmaceutical company specialised in psychiatric and neurological disorders, and healthcare company Otsuka Pharmaceutical Co Ltd (Otsuka) [...]

Oct 11, 2016 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Intellipharmaceutics International (NasdaqCM:IPCI) (TSX:I) reported on Friday the receipt of tentative approval from the US Food and Drug Administration (FDA) [...]

Aug 05, 2016 (TheFlyOnTheWall.com via COMTEX) -- 05:18 EDT Allergan, Richter provide update on cariprazine program|Allergan and Gedeon Richter provided a clinical and regulatory update on cariprazine. Cariprazine was approved [...]

PORT WASHINGTON, Mar 23, 2016 (GLOBE NEWSWIRE via COMTEX) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and [...]

Mar 16, 2016 (TheFlyOnTheWall.com via COMTEX) -- 08:02 EDT Allergan's Vraylar for bipolar mania and schizophrenia available in the U.S. - Allergan's Vraylar, a once-daily oral atypical antipsychotic, is now [...]

Byline: DETROIT, MI, Feb 01, 2016 (Marketwired via COMTEX) -- Almost six million Americans have bipolar disorder, a serious form of depression that too often leads to suicide. On February [...]

Byline: Zacks Equity Research Sep 19, 2015 (Zacks.com via COMTEX) -- Allergan plc AGN and Hungary-based partner Gedeon Richter Plc. announced that the FDA has approved their Vraylar (cariprazine) capsules [...]

Sep 18, 2015 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Allergan (NYSE:AGN) and Gedeon Richter Thursday jointly announced the receipt of US Food and Drug Administration (FDA) approval for VRAYLAR [...]

Sep 17, 2015 (TheFlyOnTheWall.com via COMTEX) -- 14:31 EDT Allergan, Gedeon Richter announce FDA approval of VRAYLAR - Allergan and Gedeon Richter announced that the U.S. FDA has approved VRAYLAR [...]

May 11, 2015 (TheFlyOnTheWall.com via COMTEX) -- 06:40 EDT Actavis sees Eluxadoline, Cariprazine PDUFAs in Q2 - Actavis said the PDUFA date for Eluxadoline, an investigational drug for the treatment [...]

Mar 16, 2015 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Actavis (NYSE:ACT) revealed on Friday the receipt of the US Food and Drug Administration's (FDA) approval for its supplemental new [...]

Mar 13, 2015 (TheFlyOnTheWall.com via COMTEX) -- 08:03 EDT Actavis receives FDA approval SAPHRIS for pediatric patients - Actavis announced that the FDA has approved its supplemental new drug application [...]

Washington, DC, Jan 06, 2015 (MidnightTrader via COMTEX) -- Actavis (ACT) Tuesday reported that the U.S. FDA has acknowledged receipt of ACT's New Drug Application (NDA) resubmission for its drug [...]

Washington, DC, Nov 13, 2014 (MidnightTrader via COMTEX) -- Actavis (ACT) said Thursday the U.S. Food and Drug Administration has accepted for filing its supplemental new drug application for Saphris [...]

Washington, DC, Aug 14, 2014 (MidnightTrader via COMTEX) -- Alexza Pharmaceuticals (ALXA) on Thursday provided an update on its European Medicines Agency (EMA) post-approval studies for its Adasuve inhalation therapy [...]

May 14, 2014 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Mylan Inc (Nasdaq:MYL) announced on Wednesday that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5mg, 10mg, 15mg and 20mg, [...]

May 14, 2014 (TheFlyOnTheWall.com via COMTEX) -- 07:32 EDT Mylan launches generic Zyprexa Zydis tabletsEli Lilly - Mylan (MYL) has launched Olanzapine Orally Disintegrating Tablets 5 mg, 10 mg, 15 [...]

Dec 20, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/cbjj6c/global_bipolar) has announced the addition of the 'Global Bipolar Disorders Drug Pipeline Capsule - 2012 Update' report to their [...]

Aug 30, 2012 (M2 EQUITYBITES via COMTEX) -- Biotechnology company Elan Corporation plc (NYSE:ELN) said on Wednesday that it has dosed the first patient in a Phase 2, placebo-controlled, safety [...]

Aug 13, 2012 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Mylan Inc (NasdaqGS:MYL) said on Friday that it has received the final approval from the US Food and Drug Administration [...]

Apr 25, 2012 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Mylan Inc (Nasdaq:MYL) reported on Tuesday the receipt of final approval from the US Food and Drug Administration (FDA) for [...]

Mar 29, 2012 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Mylan Inc (Nasdaq:MYL) reported on Wednesday the receipt of final approval from the US Food and Drug Administration (FDA) for [...]

Jan 18, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/00ac3b/global_bipolar_dis) has announced the addition of the 'Global Bipolar Disorders Drug Pipeline Capsule - 2012' report to their offering. [...]

Byline: MarketNewsVideo.com Dec 13, 2011 (MarketNewsVideo.com via COMTEX) -- Alexza Pharmaceuticals (ALXA) said today the U.S. Food and Drug Administration's psychopharmacologic advisory committee voted to recommend its schizophrenia and bipolar [...]

Oct 28, 2011 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Alexza Pharmaceuticals Inc (Nasdaq:ALXA) revealed on Thursday the submission of its ADASUVE Marketing Authorisation Application (MAA) to the European Medicines [...]

Aug 08, 2011 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Alexza Pharmaceuticals Inc (Nasdaq:ALXA) revealed on Friday the resubmission of its AZ-004 New Drug Application (NDA) to the US Food [...]